A, Immunoblotting analysis of SUIT-2 cells untreated or treated with MCM or MCM+IGF-blocking antibody for 3 hours. B, Quantification of cell death in SUIT-2 cells treated with gemcitabine, MCM, and IGF-blocking antibody for 24 hours. Error bars, SD. (n = 3); **, P ≤ 0.01; *, P ≤ 0.05 using one-way ANOVA and Tukey post hoc test. C, Quantification of cell death in primary mouse KPC-derived pancreatic cancer cells untreated or treated with gemcitabine, MCM, IGF-blocking antibody, or recombinant IGF for 24 hours. Error bars, SD. (n = 3); ***, P ≤ 0.005 using one-way ANOVA and Tukey post hoc test. D, Representative flow cytometry dot blots of KPC-derived cells exposed to gemcitabine, MCM, IGF-blocking antibody, and recombinant IGF. E, Immunoblotting analysis of PARP and tubulin in human SUIT-2 pancreatic cancer cells and cleaved caspase-3 and tubulin in KPC-derived mouse pancreatic cancer cells untreated, treated with gemcitabine, MCM + gemcitabine, or recombinant IGF + gemcitabine for 24 hours. F, Quantification of cell death in KPC-derived cells cultured in the presence or absence of MCM or recombinant IGF and treated with 10, 100, or 1,000 nmol/L nab-paclitaxel for 36 hours. Error bars, SD (n = 3); ***, P ≤ 0.005; **, P ≤ 0.01 using one-way ANOVA and Tukey post hoc test.